41.81
0.33 (0.80%)
| Penutupan Terdahulu | 41.48 |
| Jumlah Dagangan | 10,807,236 |
| Harga / Jualan (P/S) | 3.88 |
| Harga / Buku (P/B) | 7.08 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -4,823.84% |
| EPS Cair (TTM) | -0.750 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -16.10% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -96.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.93% |
| Nisbah Semasa (MRQ) | 33.47 |
| Aliran Tunai Operasi (OCF TTM) | -839.45 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -375.20 M |
| Pulangan Atas Aset (ROA TTM) | -10.73% |
| Pulangan Atas Ekuiti (ROE TTM) | -12.54% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Roivant Sciences Ltd. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | -1.00 |
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Large Core |
| % Dimiliki oleh Orang Dalam | 30.31% |
| % Dimiliki oleh Institusi | 83.49% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| VENKER ERIC | - | 34.71 | -200,000 | -6,942,000 |
| Jumlah Keseluruhan Kuantiti Bersih | -200,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -6,942,000 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 34.71 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| VENKER ERIC | Pegawai | 28 Aug 2026 | Jual automatik (-) | 200,000 | 34.71 | 6,942,000 |
| VENKER ERIC | Pegawai | 28 Aug 2026 | Pelaksanaan pilihan | 200,000 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |